Back to Authors

Redenbaugh, Vyanka

0000-0001-6400-7760

Mayo Clinic

From the Department of Neurology and Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology (L.C., J.J.C., S.B.S.-M., V.R., J.-M.T., S.J.P., E.P.F.), Mayo Clinic, Rochester, MN; Queen Square MS Centre (O.A.-M., D.C., C.H., O.C., Y.H.), UCL Quee

Citations 4

Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS
Redenbaugh, Vyanka , McCombe, Jennifer A. , Tillema, Jan‐Mendelt , Chen, John J. , López‐Chiriboga, A. Sebastian , Sechi, Elia , Pittock, Sean J, Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Chia, Nicholas H , Lopez-Chiriboga, A Sebastian , Sechi, Elia , Pittock, Sean J , Flanagan, E P , Chen, John J , Redenbaugh, Vyanka , Chia, Nicholas , Cacciaguerra, Laura , Hacohen, Yael , Flanagan, Eoin P.

Multiple Sclerosis Journal | May 23, 2023 | Volume: 29 | Issue: 7 | Pages: 799-808

10.1177/13524585231166834 Get It

Background: Magnetic resonance imaging (MRI) T2-lesions resolve more often in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) than aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and multiple sclerosis (MS) in adults but few studies analyzed children. Objective: The main objective of this study is to investigate MRI T2-lesion evolution in pediatric MOGAD, AQP4 + NMOSD, and MS. Methods: Inclusion criteria were as follows: (1) first clinical attack; (2) abnormal MRI (⩽6 weeks); (3) follow-up MRI beyond 6 months without relapses in that region; and (4) age < 18 years. An index T2-lesion (symptomatic/largest) was identified, and T2-lesion resolution or persistence on follow-up MRI was determined. Results: We included 56 patients (MOGAD, 21; AQP4 + NMOSD, 8; MS, 27) with 69 attacks. Index T2-lesion resolution was more frequent in MOGAD (brain 9 of 15 [60%]; spine 8 of 12 [67%]) than AQP4 + NMOSD (brain 1 of 4 [25%]; spine 0 of 7 [0%]) and MS (brain 0 of 18 [0%]; spine 1 of 13 [8%]), p < 0.01. Resolution of all T2-lesions occurred more often in MOGAD (brain 6 of 15 [40%]; spine 7 of 12 [58%]) than AQP4 + NMOSD (brain 1 of 4 [25%]; spine 0 of 7 [0%]), and MS (brain 0 of 18 [0%]; spine 1 of 13 [8%]), p < 0.01. Reductions in median index T2-lesion area were greater in MOGAD (brain, 305 mm; spine, 23 mm) than MS (brain, 42 mm [ p<0.001]; spine, 10 mm [ p<0.001]) without differing from AQP4 + NMOSD (brain, 133 mm [ p=0.42]; spine, 19.5 mm [ p=0.69]). Conclusion: In children, MRI T2-lesions resolved more often in MOGAD than AQP4 + NMOSD and MS which is similar to adults suggesting these differences are related to pathogenesis rather than age.
Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis
Chia, Nicholas , Redenbaugh, Vyanka , Chen, John J. , Pittock, Sean J, Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Chia, Nicholas H , Pittock, Sean J , Flanagan, E P , Chen, John J , Redenbaugh, Vyanka , Flanagan, Eoin P.

Multiple Sclerosis Journal | January 24, 2023 | Volume: 29 | Issue: 6 | Pages: 748-752

10.1177/13524585221150743 Get It

Background: Data on corpus callosum involvement in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited. Objective: The objective of the study was to compare callosal lesions in MOGAD, multiple sclerosis (MS), and aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Results: Callosal lesion frequency was similar in MOGAD (38/171 (22%)), MS (24/72 (33%)), and AQP4+NMOSD (18/63 (29%)). Clinical phenotypes included encephalopathy (47%) and focal supratentorial (21%) or infratentorial (45%) deficits. None had callosal-disconnection syndromes. Maximal callosal-T2-lesion diameter (median (range)) in millimeter was similar in MOGAD (21 (4–77)) and AQP4+NMOSD (22 (5–49); p = 0.93) but greater than in MS (10.5 (2–64)). Extracallosal extension (21/38 (55%)) and T2-lesion resolution (19/34 (56%)) favored MOGAD. Conclusions: Despite similar frequency and imaging overlap, larger lesions, sagittal midline involvement, and lesion resolution favored MOGAD.
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
Redenbaugh, Vyanka , Montalvo, Mayra , Sechi, Elia , Fryer, James P., Lennon, Vanda A. , Mills, John R. , Wingerchuk, Dean M. , Chen, John J. , Bhatti, M. Tariq , López‐Chiriboga, A. Sebastian , Pittock, Sean J, Pittock, Sean J. , Lopez-Chiriboga, A Sebastian , Pittock, Sean J , Flanagan, E P , Pittock, S J , Chen, John J , Sechi, Elia , Redenbaugh, Vyanka , Buciuc, Marina , McKeon, Andrew , Weinshenker, Brian G. , Flanagan, Eoin P.

Multiple Sclerosis Journal - Experimental, Translational and Clinical | November 26, 2021 | Volume: 7 | Issue: 4 | Pages: No page available

10.1177/20552173211052656 Get It

Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.